DK2499139T3 - N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere - Google Patents

N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere

Info

Publication number
DK2499139T3
DK2499139T3 DK10776438.3T DK10776438T DK2499139T3 DK 2499139 T3 DK2499139 T3 DK 2499139T3 DK 10776438 T DK10776438 T DK 10776438T DK 2499139 T3 DK2499139 T3 DK 2499139T3
Authority
DK
Denmark
Prior art keywords
pyrazolospiroketon
acetyl
coa carboxylase
carboxylase
coa
Prior art date
Application number
DK10776438.3T
Other languages
English (en)
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK2499139T3 publication Critical patent/DK2499139T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10776438.3T 2009-11-10 2010-10-29 N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere DK2499139T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Publications (1)

Publication Number Publication Date
DK2499139T3 true DK2499139T3 (da) 2014-01-27

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10776438.3T DK2499139T3 (da) 2009-11-10 2010-10-29 N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere

Country Status (39)

Country Link
US (4) US8288405B2 (da)
EP (3) EP2676958B1 (da)
JP (1) JP5114610B1 (da)
KR (2) KR101478517B1 (da)
CN (1) CN102695708B (da)
AP (1) AP3283A (da)
AR (1) AR078944A1 (da)
AU (1) AU2010317501B2 (da)
BR (1) BR112012011072A2 (da)
CA (1) CA2778886C (da)
CL (1) CL2012000999A1 (da)
CO (1) CO6541569A2 (da)
CR (1) CR20120190A (da)
CU (1) CU24077B1 (da)
DK (1) DK2499139T3 (da)
DO (1) DOP2012000128A (da)
EA (1) EA020153B1 (da)
EC (1) ECSP12011880A (da)
ES (1) ES2444543T3 (da)
GE (1) GEP20146169B (da)
HN (1) HN2012000973A (da)
HR (1) HRP20140025T1 (da)
IL (1) IL219373A (da)
MA (1) MA33734B1 (da)
MX (1) MX2012005429A (da)
NI (1) NI201200089A (da)
NZ (1) NZ599815A (da)
PE (1) PE20121469A1 (da)
PH (1) PH12012500903A1 (da)
PL (1) PL2499139T3 (da)
PT (1) PT2499139E (da)
RS (1) RS53156B (da)
SI (1) SI2499139T1 (da)
TN (1) TN2012000192A1 (da)
TW (1) TWI394756B (da)
UA (1) UA102336C2 (da)
UY (1) UY33020A (da)
WO (1) WO2011058474A1 (da)
ZA (1) ZA201204231B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
PT2499139E (pt) 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
HUE025078T2 (en) * 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PE20141187A1 (es) * 2011-04-22 2014-09-18 Pfizer Inhibidores sustituidos de aeitl-coa carboxilasa
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
US9133166B2 (en) 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6660060B2 (ja) 2014-09-16 2020-03-04 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
EA201790604A1 (ru) * 2014-09-17 2017-09-29 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистондеметилазы
EP3228731B1 (en) 2014-11-10 2020-04-22 National University Corporation Yokohama National University Oxygen-generating anode
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CA3068623A1 (en) 2017-06-30 2019-01-03 Quixgen, Inc. Novel spirolactone compounds
IL313710A (en) 2017-11-21 2024-08-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
WO2019178480A1 (en) * 2018-03-15 2019-09-19 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
EP4154880A4 (en) 2020-05-21 2024-06-05 Shionogi & Co., Ltd Pharmaceutical for treating fatty liver diseases
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
CN120019059A (zh) * 2022-07-29 2025-05-16 辉瑞公司 新型acc抑制剂
WO2025133948A1 (en) * 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
GEP20053710B (en) 2001-02-28 2005-12-26 Merck & Co Inc Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20080036041A (ko) 2005-07-19 2008-04-24 머크 앤드 캄파니 인코포레이티드 아세틸 조효소 카복실라제(ａｃｃ) 억제제로서의스피로크로마논 유도체
WO2007013691A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EP2097420B1 (en) * 2006-11-29 2012-04-04 Pfizer Products Inc. Spiroketone inhibitors of acetyl-coa carboxylase
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JPWO2008102749A1 (ja) 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
CA2683695C (en) * 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US20100211592A1 (en) * 2007-07-20 2010-08-19 Mark Jonathon Brownlee Email response time expectation system
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724603A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
WO2010008521A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
CA2736409C (en) * 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
PT2499139E (pt) 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
JP2013510191A (ja) 2009-11-10 2013-03-21 ファイザー・インク Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
PE20141187A1 (es) * 2011-04-22 2014-09-18 Pfizer Inhibidores sustituidos de aeitl-coa carboxilasa

Also Published As

Publication number Publication date
US8288405B2 (en) 2012-10-16
AU2010317501A1 (en) 2012-05-17
HRP20140025T1 (hr) 2014-02-14
WO2011058474A8 (en) 2012-04-26
PH12012500903A1 (en) 2014-09-24
TWI394756B (zh) 2013-05-01
NI201200089A (es) 2012-08-20
US20140288111A1 (en) 2014-09-25
JP5114610B1 (ja) 2013-01-09
ES2444543T3 (es) 2014-02-25
KR101478517B1 (ko) 2015-01-02
CU20120071A7 (es) 2013-05-31
CR20120190A (es) 2012-05-24
US20130296319A1 (en) 2013-11-07
MX2012005429A (es) 2012-06-19
CL2012000999A1 (es) 2012-07-20
EP2676958B1 (en) 2015-07-01
CN102695708B (zh) 2014-10-15
AR078944A1 (es) 2011-12-14
CU24077B1 (es) 2015-03-30
HK1173724A1 (en) 2013-05-24
IL219373A (en) 2014-04-30
CO6541569A2 (es) 2012-10-16
JP2013510192A (ja) 2013-03-21
KR20140034919A (ko) 2014-03-20
DOP2012000128A (es) 2012-08-31
AP2012006269A0 (en) 2012-06-30
AU2010317501B2 (en) 2013-06-06
US20130030181A1 (en) 2013-01-31
CA2778886C (en) 2014-01-07
EP2499139A1 (en) 2012-09-19
RS53156B (sr) 2014-06-30
EA201290191A1 (ru) 2012-12-28
KR20120099460A (ko) 2012-09-10
PL2499139T3 (pl) 2014-04-30
CN102695708A (zh) 2012-09-26
EP2676958A1 (en) 2013-12-25
NZ599815A (en) 2013-04-26
SI2499139T1 (sl) 2014-01-31
EA020153B1 (ru) 2014-09-30
UY33020A (es) 2011-06-30
KR101550557B1 (ko) 2015-09-04
EP2947082A1 (en) 2015-11-25
TN2012000192A1 (fr) 2013-12-12
US9139587B2 (en) 2015-09-22
US8802690B2 (en) 2014-08-12
CA2778886A1 (en) 2011-05-19
MA33734B1 (fr) 2012-11-01
ZA201204231B (en) 2013-02-27
HN2012000973A (es) 2015-03-02
ECSP12011880A (es) 2012-07-31
US20110111046A1 (en) 2011-05-12
EP2499139B1 (en) 2013-12-11
IL219373A0 (en) 2012-06-28
GEP20146169B (en) 2014-09-25
US8507681B2 (en) 2013-08-13
UA102336C2 (uk) 2013-06-25
TW201127838A (en) 2011-08-16
WO2011058474A1 (en) 2011-05-19
BR112012011072A2 (pt) 2017-06-20
PT2499139E (pt) 2014-02-10
AP3283A (en) 2015-05-31
PE20121469A1 (es) 2012-11-01

Similar Documents

Publication Publication Date Title
NL301334I2 (nl) vilobelimab
NO2024011I1 (no) Quizartinib
NL300964I2 (nl) Durvalumab
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
DK2414015T3 (da) Laryngoskopsystem
DK2411442T4 (da) Umættet polyesterresin
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
EP2509489A4 (en) SPRINKLER FOR EARLY HEEL REMOVAL
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
DE112009005323A5 (de) Hebelarmprüfmaschine
DK2519512T3 (da) N1-acyl-5-fluorpyrimidinonderivater
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
DK2483126T3 (da) Skinnekøretøj
DE112010004865T8 (de) Lamellennassreibkupplung
DK2506968T3 (da) Faujasit-zeolit
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
EP2398476A4 (en) Policosanol nanoparticles